The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).
 
Yasutaka Sukawa
Honoraria - Ono Pharmaceutical
 
Akitaka Makiyama
No Relationships to Disclose
 
Taito Esaki
Honoraria - Kyowa Hakko Kirin; Lilly
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Gen Hirano
No Relationships to Disclose
 
Masato Komoda
No Relationships to Disclose
 
Tomomi Kashiwada
No Relationships to Disclose
 
Junji Kawada
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Tsuda
No Relationships to Disclose
 
Akihito Tsuji
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Hiroaki Tanioka
No Relationships to Disclose
 
Kimio Yonesaka
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Patents pending joint application with Daiichi-Sankyo
 
Kazuto Nishio
No Relationships to Disclose
 
Katsuhiko Nosho
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ichinosuke Hyodo
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo; Gilead Sciences; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Shionogi